Clinical Trials
38 trialsGlofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Peking University Third Hospital
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
REPIFIR
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
EpLCART
Peter MacCallum Cancer Centre, Australia
CONFIRM
Assistance Publique - Hôpitaux de Paris
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Peter MacCallum Cancer Centre, Australia
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
RV-NHL-PI351
IRCCS San Raffaele
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Relyage
Centre Hospitalier Universitaire, Amiens
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
Fox Chase Cancer Center
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
University of Athens
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Boston VA Research Institute, Inc.
REVRI
Institut Curie
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
University of California, San Francisco
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
LeMLAR
University Hospital, Essen
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
LEGEND
Royal Marsden NHS Foundation Trust
rev/abraxane
NYU Langone Health
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
Sun Yat-sen University
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
Fondazione EMN Italy Onlus
DexTR
Weill Medical College of Cornell University
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Duke University
Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma
Karolinska University Hospital
Lenalidomide Plus Chemotherapy for AML
Massachusetts General Hospital
Cetuximab and Lenalidomide in Head and Neck
University of Chicago
LLC-LENAR-08
MD Anderson International Spain SA
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma
Gruppo Italiano Studio Linfomi
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
University of Bologna
MM03
University of Regensburg
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
University of Wuerzburg